Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Health Care and Management/健康管理學院
  3. Department of Nutritional Science/營養學系
  4. 青梅加工品抗代謝症候群功能及其保健產品開發-以人體試食試驗評估梅精複方輔助調節血壓之研究
 
  • Details
Options

青梅加工品抗代謝症候群功能及其保健產品開發-以人體試食試驗評估梅精複方輔助調節血壓之研究

Date Issued
2021
Author(s)
鄭涵輝
Han-Hui Chang
Advisor
黃詩茜;徐慶琳
Shih-Chien Huang;Chin-Lin Hsu
URI
https://handle.ncl.edu.tw/11296/d6ca5x
https://scholars.csmu.edu.tw/handle/123456789/7138
Abstract
代謝症候群是台灣嚴重的健康問題,其與國人十大死因之糖尿病、高血壓與心臟病等息息相關,若不加以預防與治療可能會引起許多慢性併發症。高血壓的盛行率會隨著年齡之增長而增加,根據統計,台灣兩千三百萬人中,約有24%的人患有高血壓,尤其是60歲以上的年長者,每兩人中就有一人患有高血壓,因而導致每六人就有一人會發生中風,治療高血壓方式除了生活型態改變外,最直接方式為藥物治療,即便高血壓藥物已經發展出許多標準療程,但也出現許多副作用,使得民眾不樂於接受藥物治療。所以本研究希望透過其他方式來改善高血壓。根據先前文獻指出,青梅具有降低血脂、體脂肪及血糖之功能,由於傳統梅精在製作過程中需經長時間加熱,造成梅果實中所含機能性成分被破壞,因而降低其有益功能與價值性。因此研究使用之梅精是配合減壓濃縮方式,減少加熱溫度及時間製成之新型梅精為基礎,外加不同比例青梅果實、黑蒜和仙草萃取物製成梅精複方,透過加強其機能性成分如綠原酸 (chlorogenic acid)、咖啡酸 (caffeic acid)、p-香豆酸 (p-coumaric acid) 等,開發出新穎性梅精複方,並以抗代謝症候群為訴求,先前本研究室已釐清並透過不易形成體脂肪、降血脂和調節血糖之實驗篩選出具潛力之樣品,梅精複方-4號 (Mei-Gin Formula-4, MGF-4) 及梅精複方-7號 (Mei-Gin Formula-7, MGF-7),然而,目前尚未進行梅精複方對血壓影響之臨床試驗,來完成此複方在抗代謝症候群之作用。因此,本研究透過隨機、單盲、介入型人體試食試驗,評估梅精複方對於血壓的影響和安全性。招募50位患有高血壓 (收縮壓介於130-179 mmHg或舒張壓介於85-109 mmHg),未服用高血壓藥物受試者,將其隨機分配到梅精複方-4號或梅精複方-7號之組別,實驗時間為期八週,每日食用梅精複方-4號或梅精複方-7號4顆,最後共44人完成試驗。由實驗結果得知,在MGF-4介入第4及8週之收縮壓 (Systolic blood pressure, SBP) 及舒張壓 (Diastolic blood pressure, DBP) 與第0週相比顯著下降 (p<0.05);在MGF-7介入第4及8週之SBP與DBP與第0週相比顯著下降 (p<0.05);而在MGF-4及MGF-7兩種梅精複方介入後,兩組別之間降血壓效果並無統計差異 (p>0.05)。另外,在子群體分析,依據性別、年齡及BMI分群,介入MGF-4或MGF-7後血壓均顯著下降 (p<0.05)。血清nitrite及nitrate於MGF-4或MGF-7介入8週後與第0週相比,顯著上升 (p<0.05)。血清總抗氧化能力 (Trolox equivalent antioxidant capacity, TEAC) 於MGF-4或MGF-7介入8週後與第0週相比,皆顯著上升 (p<0.05)。血清脂質過氧化物丙二醛 (malondialdehyde, MDA),則在MGF-4介入8週後與第0週相比,顯著下降。另外利用肝、腎以及血清離子濃度指標評估梅精複方之安全性,結果顯示MGF-4及MGF-7介入為期8週後,AST、ALT、BUN、Na+、K+、Ca2+及PO43-皆無造成負面之影響。綜合以上結果可知,MGF-4及MGF-7均具有調節血壓之作用,因此未來可做為調節血壓之保健食品開發之運用。
Metabolic syndrome is a rising public health issue, which is closely associated with the development of diabetes mellitus, hypertension, and cardiovascular disease that presents in ten leading cause of death in Taiwan. Untimely treatment and prevention action increased the risk of numerous metabolic syndrome associated chronic complications. The prevalence of hypertension increases with age. Statistics indicated that 24% of 23 million population has hypertension in Taiwan. Particularly of the elderly individual age over 60 with one in every two were considered to have hypertension and subsequently about one in every six people result in stroke. In addition to lifestyle change, medication is the most direct way that is used to treat hypertension. Although the standard procedure for treating hypertension has been well established, the side-effect experience leads to unwillingness for patients to accept medication. In the present study, we aim to develop a novel therapeutic method for improving hypertension. Previous studies indicated that Prunus mume exerted beneficial effects on improving hyperlipidemia, hyperglycemia, and decreasing an excessive body fat accumulation. During a long-term heating period at high temperature, functional compounds of Prunus mume can be destroyed, and thus decreased its functional values. Here, concentration process under reduced pressure condition was performed to form a novel type of bainiku-ekisu. Then, we have developed novel bainiku-ekisu based herbal formulas with additional extracts from Prunus mume, black garlic, and Mesona procumbens Hemsl. to increase functional components, including chlorogenic acid, caffeic acid, and p-coumaric acid, called Mei-Gin formulas (MGFs). According to our preliminary investigation previously of serials MGFs were demonstrated that Mei-Gin formula-4 (MGF-4) and Mei-Gin formula-7 (MGF-7) showed optimal benefits on improving body fat accumulation, hyperlipidemia, and hyperglycemia. However, the effects of MGFs on regulating hypertension by conducting clinical trial was remain uncleared. Thus, a randomized, and single-blind trial was designed to evaluate the effects of MGFs on blood pressure. 50 participants with hypertension (systolic blood pressure between 130-179 mmHg or diastolic blood pressure between 85-109 mmHg) who did not accept any hypertension medication were randomized allocated to either MGF-4 or MGF-7 group. Participants were instructed to take 4 capsules of MGF-4 or MGF-7 daily throughout the duration of the study. After 8 weeks intervention, only 44 participants completed the study, while 22 participants each completely took MGF-4 and MGF-7 throughout of the experiment respectively. The results showed that after MGF-4 intervention, the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of week 4 and 8 were significantly decreased as compared those of week 0 (p<0.05). Compared to week 0, MGF-7 significantly decreased SBP and DBP at week 4 and 8 (p<0.05). However, the antihypertensive effect between MGF-4 and MGF-7 showed no statistical difference (p>0.05). Subgroup analysis by gender, age, and body mass index showed that either MGF-4 or MGF-7 intervention significantly decreased blood pressure (p<0.05). After 8 weeks intervention of both MGF-4 and MGF-7, serum nitrite, nitrate, and trolox equivalent antioxidant capacity (TEAC) were founded to significantly increased, while plasma malondialdehyde (MDA) was significantly decreased after MGF-4 intervention (p<0.05). In addition, indices of liver and kidney function, and serum ion concentration were used to evaluate the biosafety of MGFs. Furthermore, no adverse effects were observed in AST, ALT, BUN, Na+, K+, Ca2+, and PO43-. In conclusion, both MGF-4 and MGF-7 exhibited beneficial effects on improving blood pressure and suggested to as a potential health supplement against hypertension.
Subjects
梅精複方
酚酸類
代謝症候群
調節血壓
Mei-Gin Formula
phenolic acid
metabolic syndrome
regulate blood pressure
Type
thesis
File(s)
No Thumbnail Available
Name

109CSMU5513001-001.zip

Size

3.49 MB

Format

Unknown

Checksum

(MD5):c0f29352b05e08f6d54865adf0aceab9

Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback